ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2017

Abstract Number: 2099

Elderly – Onset Sarcoidosis: a Single Center Comparative Study

Senol Kobak1, Fidan Yildiz2, Huseyin Semiz3 and Mehmet Orman4, 1Rheumatology, Istinye University Faculty of Medicine, Istanbul, Turkey, 2Chest Diseases, Medicalpark Hospital, İzmir, Turkey, 3Internal Medicine, Ege University Faculty of Medicine, İzmir, Turkey, 4Statistics, Ege University Faculty of Medicine, İzmir, Turkey

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2017

Date of first publication: September 18, 2017

Keywords: sarcoidosis

Session Information

Date: Tuesday, November 7, 2017

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Sarcoidosis is a chronic granulomatous inflamatory disease characterized with non-caseified granuloma formation. It is rarely affects patients older than 65 years old..The purpose of this study is to compare and evaluate the demografic, clinical and laboratory features of elderly-onset(EOS) and young-onset sarcoidosis(YOS) patients.

Methods:

One hundred and thirty one patients diagnosed with sarcoidosis according to clinical, radiologic and histopathological evaluation were included in this study.The patients with initial symptoms started after age 65 were accepted as EOS. Demografic, clinic, radiologic, and laboratory data and the medication which the patients recieved were recorded and retrospectively evaluated.

Results:

Twenty(15.3%)of 131 patients were diagnosed as EOS, and 111(84.7%) patients were evaluated as YOS. Fifteen of 20 EOS patients were female and 5 of them were male. Average duration of the disease was determined as 38.4months for YOS and 22.5months for EOS(p=0.556).Delay of the diagnosis was 12months for YOS while it was 3months for EOS(p=0.001).Higher rates of fatique, comorbid diseases and more Hydroxychloroquine(HQ) use were detected in EOS patients comparing to YOS(p=0.010, p=0.003 and p=0.039 respectively).There was obviously more disease modifying anti-rheumatic drugs(DMARDs) use by YOS group but statistical difference wasn’t significant. The 3-year survival rate after diagnosis of sarcoidosis was %95 in the EOS group, compared with %100 in the YOS group

Conclusion:

In this study we showed that YOS and EOS patients may be presented with different clinical, and laboratory features. EOS patients are characterized with higher rates of fatique and comorbid diseases, less inflammatory sign and delayed diagnosis, and less DMARDs usage.


Disclosure: S. Kobak, None; F. Yildiz, None; H. Semiz, None; M. Orman, None.

To cite this abstract in AMA style:

Kobak S, Yildiz F, Semiz H, Orman M. Elderly – Onset Sarcoidosis: a Single Center Comparative Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/elderly-onset-sarcoidosis-a-single-center-comparative-study/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/elderly-onset-sarcoidosis-a-single-center-comparative-study/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology